NASDAQ:IDXXIDEXX Laboratories Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding IDEXX Laboratories, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $249.73 +15.18 (+6.47 %) (As of 04/6/2020 10:18 AM ET) Add Compare Share Today's Range$243.37Now: $249.73▼$250.1550-Day Range$182.94MA: $247.65▼$290.9752-Week Range$168.65Now: $249.73▼$296.25Volume66,798 shsAverage Volume1.11 million shsMarket Capitalization$21.31 billionP/E Ratio51.17Dividend YieldN/ABeta0.76 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.Read More Beat the Market (BTM) Rank™ 2.4 Analyst's Opinion Consensus RatingIDEXX Laboratories has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $293.33, IDEXX Laboratories has a potential upside of 20.0% from its current price of $244.51.Amount of Analyst CoverageIDEXX Laboratories has received no research coverage in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesIDEXX Laboratories has received 466 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIDEXX Laboratories has received 340 “underperform” votes. (Add your “underperform” vote.)Community SentimentIDEXX Laboratories has received 57.82% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about IDEXX Laboratories and other stocks. Vote “Outperform” if you believe IDXX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IDXX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIDEXX Laboratories does not currently pay a dividend.Dividend GrowthIDEXX Laboratories does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IDEXX Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,493,168.00 in company stock.Percentage Held by InsidersOnly 2.70% of the stock of IDEXX Laboratories is held by insiders.Percentage Held by Institutions87.33% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IDEXX Laboratories are expected to grow by 17.48% in the coming year, from $5.32 to $6.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IDEXX Laboratories is 50.10, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 11.39.Price to Earnings Ratio vs. SectorThe P/E ratio of IDEXX Laboratories is 50.10, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 19.67.Price to Book Value per Share RatioIDEXX Laboratories has a P/B Ratio of 118.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.39 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:IDXX Previous Symbol CUSIP45168D10 CIK874716 Webhttp://www.idexx.com/ Phone207-556-0300Debt Debt-to-Equity Ratio4.31 Current Ratio0.94 Quick Ratio0.67Price-To-Earnings Trailing P/E Ratio51.17 Forward P/E Ratio46.94 P/E GrowthN/A Sales & Book Value Annual Sales$2.41 billion Price / Sales8.85 Cash Flow$6.40 per share Price / Cash Flow39.01 Book Value$2.07 per share Price / Book120.64Profitability EPS (Most Recent Fiscal Year)$4.89 Net Income$427.72 million Net Margins17.77% Return on Equity283.27% Return on Assets24.48%Miscellaneous Employees9,200 Outstanding Shares85,340,000Market Cap$21.31 billion Next Earnings Date5/6/2020 (Estimated) OptionableOptionable Receive IDXX News and Ratings via Email Sign-up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:IDXX Rates by TradingView IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions How has IDEXX Laboratories' stock been impacted by COVID-19 (Coronavirus)? IDEXX Laboratories' stock was trading at $245.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IDXX stock has decreased by 0.4% and is now trading at $244.51. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of IDEXX Laboratories? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IDEXX Laboratories. When is IDEXX Laboratories' next earnings date? IDEXX Laboratories is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for IDEXX Laboratories. How were IDEXX Laboratories' earnings last quarter? IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted its earnings results on Friday, January, 31st. The company reported $1.04 EPS for the quarter, topping the Zacks' consensus estimate of $0.91 by $0.13. The business earned $605.50 million during the quarter, compared to the consensus estimate of $600.60 million. IDEXX Laboratories had a return on equity of 283.27% and a net margin of 17.77%. The business's revenue for the quarter was up 10.2% on a year-over-year basis. During the same period last year, the firm earned $0.98 earnings per share. View IDEXX Laboratories' earnings history. How will IDEXX Laboratories' stock buyback program work? IDEXX Laboratories announced that its Board of Directors has initiated a stock repurchase program on Wednesday, February 12th 2020, which allows the company to buyback 5,000,000 outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company's management believes its shares are undervalued. What guidance has IDEXX Laboratories issued on next quarter's earnings? IDEXX Laboratories issued an update on its FY20 earnings guidance on Friday, January, 31st. The company provided earnings per share guidance of $5.42-5.58 for the period, compared to the Thomson Reuters consensus estimate of $5.41. The company issued revenue guidance of $2.62-2.66 billion, compared to the consensus revenue estimate of $2.63 billion. What price target have analysts set for IDXX? 6 equities research analysts have issued 12-month price objectives for IDEXX Laboratories' shares. Their forecasts range from $277.00 to $310.00. On average, they expect IDEXX Laboratories' share price to reach $293.33 in the next twelve months. This suggests a possible upside of 20.0% from the stock's current price. View analysts' price targets for IDEXX Laboratories. What are Wall Street analysts saying about IDEXX Laboratories stock? Here are some recent quotes from research analysts about IDEXX Laboratories stock: 1. According to Zacks Investment Research, "IDEXX exited the fourth quarter on a strong note, with better-than-expected numbers. The solid organic revenue growth during the quarter, driven by strong sales at the CAG business, is encouraging. The company witnessed sturdy gains from CAG Diagnostics in the quarter. It also saw strong performances by IDEXX VetLab consumables, reference laboratory diagnostic and consulting as well as moderately robust growth in rapid assay product revenues globally. The strong performance can also be attributed to impressive growth in the LPD and water segments. The global adoption of its latest products and services, including the rapid expansion of Catalyst installed base, is another contributing factor. Over the past three months, IDEXX has been outperforming its industry. However, operating margin contracted during the quarter." (2/4/2020) 2. Canaccord Genuity analysts commented, "We think IDXX is likely due for a new product launch around 2020 or so, but whether they announce it at the Analyst Day, or VMX remains to be seen. We reiterate our Buy on IDXX and raise our PT to $285, as we roll forward to our new 2021 estimates. Q2 beat on the bottom, delivered small miss on the top. Q2 Adj. EPS of $1.43 (+16% rep, +19% FXN) beat our $1.35/Street’s $1.37 and OM of 26.5% (+140bps Y/Y) beat our 25.4%E, as G&A came in $5M below us (disciplined expense management, low benefit costs and LPD cost controls). Q2 revs of $620M (+7% rep., +9% FXN) missed our $625M/Street’s $627M (see shortfall rationale below). GMs of 57.7% grew 50bps Y/Y and matched us (helped by 2-3% price increases, and mix benefits). Q2 rev. shortfall." (8/2/2019) Has IDEXX Laboratories been receiving favorable news coverage? News articles about IDXX stock have trended very negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. IDEXX Laboratories earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutIDEXX Laboratories. Are investors shorting IDEXX Laboratories? IDEXX Laboratories saw a increase in short interest in March. As of March 13th, there was short interest totaling 1,720,100 shares, an increase of 35.4% from the February 27th total of 1,270,000 shares. Based on an average daily volume of 670,800 shares, the short-interest ratio is presently 2.6 days. Currently, 2.0% of the shares of the company are sold short. View IDEXX Laboratories' Current Options Chain. Who are some of IDEXX Laboratories' key competitors? Some companies that are related to IDEXX Laboratories include Abbott Laboratories (ABT), Medtronic (MDT), Becton Dickinson and (BDX), Stryker (SYK), Intuitive Surgical (ISRG), Boston Scientific (BSX), Baxter International (BAX), Edwards Lifesciences (EW), DexCom (DXCM), ResMed (RMD), Teleflex (TFX), Steris (STE), Insulet (PODD), Masimo (MASI) and Varian Medical Systems (VAR). What other stocks do shareholders of IDEXX Laboratories own? Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Alibaba Group (BABA), Paypal (PYPL), Netflix (NFLX), Mastercard (MA), Adobe (ADBE), Intuitive Surgical (ISRG), Home Depot (HD), Micron Technology (MU) and Tesla (TSLA). Who are IDEXX Laboratories' key executives? IDEXX Laboratories' management team includes the following people: Mr. Jonathan W. Ayers, Chairman, CEO & Pres (Age 63)Mr. Brian P. McKeon, CFO, Exec. VP & Treasurer (Age 57)Ms. Jacqueline L. Studer, Corp. VP, Gen. Counsel & Corp. Sec. (Age 60)Mr. Giovani Twigge, Chief HR Officer & Corp. VP (Age 55)Mr. Jay Mazelsky, Exec. VP of Companion Animal Group (Age 58) What is IDEXX Laboratories' stock symbol? IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX." Who are IDEXX Laboratories' major shareholders? IDEXX Laboratories' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Woodstock Corp (0.05%), Bath Savings Trust Co (0.03%), Pensionfund Sabic (0.01%) and Cacti Asset Management LLC (0.00%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, Lawrence D Kingsley, M Anne Szostak, Michael Lane, Rebecca M Henderson, Sophie V Vandebroek and William T End. View institutional ownership trends for IDEXX Laboratories. Which institutional investors are selling IDEXX Laboratories stock? IDXX stock was sold by a variety of institutional investors in the last quarter, including Woodstock Corp, and Cacti Asset Management LLC. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Giovani Twigge, Jay Mazelsky, Jonathan W Ayers, M Anne Szostak, Michael Lane, Rebecca M Henderson, and Sophie V Vandebroek. View insider buying and selling activity for IDEXX Laboratories. Which institutional investors are buying IDEXX Laboratories stock? IDXX stock was acquired by a variety of institutional investors in the last quarter, including Bath Savings Trust Co, and Pensionfund Sabic. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin, and Lawrence D Kingsley. View insider buying and selling activity for IDEXX Laboratories. How do I buy shares of IDEXX Laboratories? Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is IDEXX Laboratories' stock price today? One share of IDXX stock can currently be purchased for approximately $244.51. How big of a company is IDEXX Laboratories? IDEXX Laboratories has a market capitalization of $20.87 billion and generates $2.41 billion in revenue each year. The company earns $427.72 million in net income (profit) each year or $4.89 on an earnings per share basis. IDEXX Laboratories employs 9,200 workers across the globe. View additional information about IDEXX Laboratories. What is IDEXX Laboratories' official website? The official website for IDEXX Laboratories is http://www.idexx.com/. How can I contact IDEXX Laboratories? IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected] This page was last updated on 4/6/2020 by MarketBeat.com StaffFeatured Article: What is a recession?
